Compare Invesco Ltd. (IVZ) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Ltd. vs Mesoblast Limited — how do they compare? Invesco Ltd. trades at $29.51 (market cap $13.28B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: Invesco Ltd. is far larger — about 7.6× Mesoblast Limited's market cap, and Invesco Ltd. pays a 2.86% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Ltd. for 77 Days and Mesoblast Limited for 15 Days on average.
| IVZ | MESO | |
|---|---|---|
Market Cap | $13.28B | $1.75B |
Volume | 3,698,033 | 239,027 |
Sector | Financials | Health |
52-Week High | $33.31 | $20.96 |
52-Week Low | $22.44 | $13.19 |
Typical Hold Time | 77 Days | 15 Days |
Enterprise Value | $23.45B | $1.83B |
Dividend Yield | 2.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IVZ trades at $30.09, down 1.34% on the day, with a bearish technical signal from moving averages and oscillators. The company reported a net loss of $281.70 million in 2025 despite revenue growth to $6.38 billion, though recent earnings beats in Q4 2025 and Q2 2026 show some operational resilience. Analyst consensus is mixed with a $33.14 price target, and the firm continues expanding its ETF suite, including the recent launch of the Invesco Nasdaq International Innovators 100 ETF.
The outlook remains cautious due to negative profitability margins and bearish technicals, but the absence of sell ratings and a dividend payment provide some support. Key risks include sustained negative net income and competitive pressures in the asset management sector, while potential upside hinges on improved earnings and AUM growth momentum.
Mesoblast (MESO) trades at $13.75, down 1.36% with bearish technical signals despite recent FDA approval for its Ryoncil potency assay. The company shows significant revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent milestones include completing Phase 3 trials for chronic back pain treatment, positioning the biotech firm for potential market expansion in the $10 billion back pain market.
Investment outlook balances promising commercial progress against persistent financial losses. The stock offers speculative growth potential through FDA-approved therapies and pipeline developments, but carries substantial risk from ongoing cash burn and competitive pressures in the regenerative medicine space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
